Collegium Pharmaceutical (COLL) Shares Down 7.1%

Collegium Pharmaceutical Inc (NASDAQ:COLL)’s share price fell 7.1% during mid-day trading on Friday . The stock traded as low as $15.61 and last traded at $15.80. 550,131 shares traded hands during trading, an increase of 20% from the average session volume of 460,290 shares. The stock had previously closed at $17.00.

A number of research analysts have recently commented on COLL shares. BidaskClub raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 5th. ValuEngine lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, January 7th. Cantor Fitzgerald set a $35.00 price objective on Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Friday, February 8th. Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective (down previously from $35.00) on shares of Collegium Pharmaceutical in a report on Wednesday, January 16th. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Wednesday, January 9th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Collegium Pharmaceutical presently has an average rating of “Buy” and an average target price of $28.50.

The stock has a market cap of $527.28 million, a P/E ratio of -13.28 and a beta of 0.35. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.26 and a quick ratio of 1.21.



Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.65. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. The business had revenue of $73.40 million during the quarter, compared to analyst estimates of $72.71 million. During the same period in the previous year, the company posted ($0.54) EPS. The firm’s revenue was up 579.6% compared to the same quarter last year. Equities analysts predict that Collegium Pharmaceutical Inc will post -0.25 EPS for the current year.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $14.81, for a total transaction of $370,250.00. Following the completion of the sale, the director now directly owns 259,430 shares in the company, valued at $3,842,158.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last 90 days, insiders have sold 75,000 shares of company stock valued at $1,188,500. Company insiders own 13.87% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. increased its holdings in shares of Collegium Pharmaceutical by 644.8% in the 4th quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after buying an additional 3,179 shares during the last quarter. Oregon Public Employees Retirement Fund purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter worth $103,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Collegium Pharmaceutical by 412.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,124 shares of the specialty pharmaceutical company’s stock worth $191,000 after acquiring an additional 8,954 shares during the last quarter. Advisory Services Network LLC purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter worth $203,000. Finally, IHT Wealth Management LLC purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter worth $219,000.

WARNING: This story was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://dakotafinancialnews.com/2019/03/24/collegium-pharmaceutical-coll-shares-down-7-1.html.

About Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.